No Data
Baird Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $72
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Soleno Therapeutics Says FDA Extends DCCR NDA Review Citing 'Major Amendment'
Express News | Soleno Therapeutics Shares Slide 13% Premarket After Co Announces US FDA Extension of Review Period for Genetic Disorder Treatment
Soleno Therapeutics Announces U.S.. FDA to Ended Review Period for NDA
Express News | Soleno: FDA Determined That Responses to Recent Information Requests Constituted a Major Amendment to Nda for Dccr Extended-Release Tablets